Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncocyte Corp (NQ: OCX )

3.150 -0.100 (-3.08%)
Streaming Delayed Price Updated: 1:19 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Oncocyte Corp

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
OncoCyte's Return On Capital Employed Insights
Via Benzinga
Precision Diagnostics Company Oncocyte Cuts 40% Of Its Workforce
Via Benzinga
Analyst Ratings for OncoCyte
Via Benzinga
Expert Ratings for OncoCyte
Via Benzinga
Oncocyte Implements Cost Reduction Initiatives, Realigns Operations
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GlycoMimetics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones settled slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Oncocyte Enters $2B Market With Transplant Rejection Monitoring Test
Via Benzinga
Expert Ratings for OncoCyte
Within the last quarter, OncoCyte (NASDAQ:OCX) has observed the following analyst ratings: 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 96 stocks hit new 52-week lows. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! Let's get right into the biggest pre-market stock movers on Monday that traders will want to watch! 
Via InvestorPlace
Why AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares rose 48.5% to $0.56 in pre-market trading. Kiromic Biopharma said the company has determined not to pursue, at this time, the contemplated public... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones dropped by around 170 points on Wednesday following the release of Fed minutes. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Expert Ratings for OncoCyte
  Over the past 3 months, 3 analysts have published their opinion on OncoCyte (NASDAQ:OCX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
Oncocyte Reports That Its First-Of-Its-Kind DetermaCNI Blood Test That Tracks Cancer Treatment Progress Could Hit Market By 2023
Image by Nguyễn Hiệp on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
OncoCyte: Q1 Earnings Insights
OncoCyte (NASDAQ:OCX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings OncoCyte reported in-line EPS of... 
Via Benzinga
Oncocyte Reports It's Ready To Enter The $3.6 Billion Transplant Diagnostics Market In First Half Of 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. The transplant diagnostics market encompasses blood tests,... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.